homebusiness Newscompanies NewsZoomed Out | Poison Pill Strategy — how successful is this defence mechanism to prevent hostile takeovers

Zoomed Out | Poison Pill Strategy — how successful is this defence mechanism to prevent hostile takeovers

A poison pill strategy is a manoeuvre that typically makes a company less palatable to a potential acquirer by making it more expensive for the acquirer to buy shares of the target company above a certain threshold. While this is being advocated as a successful mechanism to combat hostile takeovers which is potent enough to ward off the bidder or acquirer but in doing so it may cause harm to the company as well, writes Gravitas Legal's Ashni Gupta.

By Ashni Gupta  Jan 4, 2024 12:20:35 PM IST (Updated)

8 Min Read

In today's world of business, mergers and acquisitions are an indispensable part of the corporate strategy. However, not all mergers and acquisitions are welcoming with public listed companies being most exposed to threats of a hostile takeover. The coronavirus outbreak has undisputedly pushed corporate entities to vulnerable positions wherein entities have become attractive targets for hostile acquisitions because of the plummeted stock prices.
However, with time, the companies have come up with varied defence mechanisms to prevent such hostile takeovers. Amongst other anti-takeover strategies, the ‘poison pill strategy’ is being advocated as a successful mechanism to combat hostile takeovers which is potent enough to ward off the bidder or acquirer but in doing so it causes harm to the company as well. Hence, the name 'poison pill'.
Decoding the poison pill
A poison pill is a manoeuvre that typically makes a company less palatable to a potential acquirer by making it more expensive for the acquirer to buy shares of the target company above a certain threshold. In its simplest form, the poison pill is a shareholders' rights plan, which excludes the acquirer. The purpose of this move is to devalue the stock worth of the target company and dilute the percentage of the target company equity owned by the hostile acquirer to an extent that makes any further acquisition prohibitively expensive for him.